A very promising strategy to overcome certain limitations of Trastuzumab may be the use of the bispecific antibody [(HER2)2xCD16] which re-directs CD16+ γδ T cells to the tumor-associated cell surface antigen human epidermal growth factor receptor (HER)-2. This evidence concerns the gene ERBB2 and neoplasm.